RespireRx Pharmaceuticals Inc. and its subsidiaries and business units (“RespireRx Group”) are leaders in the discovery and development of medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including obstructive sleep apnea (“OSA”), attention deficit hyperactivity disorder (“ADHD”), epilepsy, pain, recovery from spinal cord injury (“SCI”), and certain neurological orphan diseases . The Company is developing a pipeline of new and re-purposed drug products based on our broad patent portfolios for two drug platforms: (i) pharmaceutical cannabinoids, which include dronabinol, a synthetic form of ∆9-tetrahydrocannabinol (“Δ9-THC”) that acts upon the nervous system’s endogenous cannabinoid receptors and (ii) neuromodulators, which include AMPAkines and GABAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) AMPA-type glutamate receptors and GABAA receptors, respectively.
Company profile
Ticker
RSPI
Exchange
Website
CEO
Arnold S. Lippa
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CORTEX PHARMACEUTICALS INC/DE/
SEC CIK
Corporate docs
Subsidiaries
Pier Pharmaceuticals, Inc. incorporated • ResolutionRx Ltd incorporated in Australia ...
IRS number
330303583
RSPI stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
16 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
2 Feb 24
8-K
RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
22 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Dec 23
10-Q
2023 Q3
Quarterly report
17 Nov 23
NT 10-Q
Notice of late quarterly filing
14 Nov 23
8-K
RespireRx Pharmaceuticals Inc.’s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
12 Oct 23
8-K
Settlement and Exchange Agreement
2 Oct 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 6.36 k | 6.36 k | 6.36 k | 6.36 k | 6.36 k | 6.36 k |
Cash burn (monthly) | 319.67 | (no burn) | 110.84 k | 117.48 k | 33.65 k | 20.63 k |
Cash used (since last report) | 2.13 k | n/a | 738.47 k | 782.71 k | 224.22 k | 137.46 k |
Cash remaining | 4.23 k | n/a | -732.11 k | -776.34 k | -217.86 k | -131.10 k |
Runway (months of cash) | 13.2 | n/a | -6.6 | -6.6 | -6.5 | -6.4 |
Institutional ownership, Q1 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|